{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:01:42Z","timestamp":1744153302668},"reference-count":9,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":5241,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1998,11]]},"abstract":"<jats:p><jats:italic>This study was designed to determine the steady\u2010state relative bioavailability of ganciclovir after three dosage regimens designed to deliver 6,000 mg\/day. The study design was an open\u2010label, randomized, three\u2010treatment crossover design in which 22 human immunodeficiency virus (HIV) and cytomegalovirus (CMV) seropositive patients received in random order multiple oral doses of ganciclovir 1,000 mg six times a day, 1,500 mg four times a day, and 2,000 mg three times a day. Blood samples were obtained on day 3 of each oral regimen over a 24\u2010hour time interval. Mean steady\u2010state average serum concentrations of ganciclovir were greater than 1.0 \u03bcg\/mL, which exceeds the median<\/jats:italic> in vitro <jats:italic>inhibitory concentration (IC<jats:sub>50<\/jats:sub>) of most CMV isolates (0.5\u20131.0 \u03bcg\/mL). All three regimens resulted in values for area under the concentration\u2014time curve from 0 to 24 hours (AUC<jats:sub>0\u201324<\/jats:sub>) that were comparable to those seen after maintenance ganciclovir intravenous infusions of 5 mg\/kg\/day. The 1,000 mg six times daily regimen resulted in an AUC<jats:sub>0\u201324<\/jats:sub> that was significantly higher than that of the 1,500 mg four times daily or the 2,000 mg three times daily regimens, although the differences were less than 12.5%<\/jats:italic>.<\/jats:p>","DOI":"10.1177\/009127009803801106","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T00:52:18Z","timestamp":1182473538000},"page":"1021-1024","source":"Crossref","is-referenced-by-count":4,"title":["Steady\u2010State Relative Bioavailability of Three Oral Ganciclovir Dosage Regimens Delivering 6,000 mg\/day in Patients with Human Immunodeficiency Virus"],"prefix":"10.1002","volume":"38","author":[{"given":"Donald","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Griffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Colburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Hulse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"194","article-title":"Cytomegalovirus infection in patients with AIDS","volume":"6","author":"Drew WL","year":"1992","journal-title":"Clin Infect Dis"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509073331002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1431"},{"key":"e_1_2_1_5_2","unstructured":"SquiresKE StempienMJ ShadmanA BuhlesWC:Oral ganciclovir versus intravenous ganciclovir maintenance therapy for cytomegalovirus retinitis in patients with AIDS: preliminary results of a phase III study. Presented at the First National Conference on Human Retroviruses and Related Infections Washington DC December 12\u201316 1993."},{"key":"e_1_2_1_6_2","first-page":"471","article-title":"Intravenous versus oral ganciclovir: European\/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS","volume":"9","author":"The Oral Ganciclovir European and Australian Cooperative Study Group","year":"1995","journal-title":"Acq Immune Deficiency Synd"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0149-2918(95)80107-3"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0928-0197(93)90012-T"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.4.833"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/358162a0"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F009127009803801106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/009127009803801106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T15:37:36Z","timestamp":1698507456000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/009127009803801106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1998,11]]}},"alternative-id":["10.1177\/009127009803801106"],"URL":"https:\/\/doi.org\/10.1177\/009127009803801106","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,11]]}}}